Perthera seeks to be the precision medicine partner on the patient’s cancer care team.
Recent breakthroughs in cellular protein analysis (proteomics) and gene profiling (genomics) make it possible for Perthera to more completely understand the nature and progression of your cancer. There are many new tests available that can give us insight into your disease, and we select the best available tests to obtain a comprehensive disease profile.
Perthera uses advanced, commercially available tests to provide your oncologist the most complete information available today for fighting your cancer.
Perthera is the only company that safeguards biopsy quality for analysis and takes into account proteomics, genomics and your past medical history. We are also the only company to provide clinical trial options tailored specifically to your molecular profile and previous treatment history.
We use an advanced expert system, an extensive clinical knowledge base, and an expert medical review panel to thoroughly understand your unique cancer and provide options to you and your physician.
Perthera provides a comprehensive report, incorporating all genomic, proteomic test results and expert review of your clinical history to enable you and your oncologist to make the best treatment decisions for you.
Recent breakthroughs in cellular protein analysis (proteomics) and gene profiling (genomics) make it possible for Perthera to more completely understand the nature and progression of your cancer. There are many new tests available that can give us insight into your disease, and we select the best available tests to obtain a comprehensive disease profile.
Perthera uses advanced, commercially available tests to provide your oncologist the most complete information available today for fighting your cancer.
Perthera is the only company that safeguards biopsy quality for analysis and takes into account proteomics, genomics and your past medical history. We are also the only company to provide clinical trial options tailored specifically to your molecular profile and previous treatment history.
We use an advanced expert system, an extensive clinical knowledge base, and an expert medical review panel to thoroughly understand your unique cancer and provide options to you and your physician.
Perthera provides a comprehensive report, incorporating all genomic, proteomic test results and expert review of your clinical history to enable you and your oncologist to make the best treatment decisions for you.
Location: United States, Virginia, McLean
Employees: 51-200
Total raised: $8.7M
Founded date: 2012
Investors 1
| Date | Name | Website |
| - | Pilot Grow... | pilotgrowt... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 30.06.2016 | - | $8.7M | - |
Mentions in press and media 14
| Date | Title | Description |
| 31.03.2025 | New Perthera Peer-Reviewed Study Reveals Metastatic Site as Key Prognostic Factor in Pancreatic Cancer | Findings published in The Oncologist underscore the need to account for metastatic site and genomic context in pancreatic cancer trial design Ignoring the biological and clinical differences between metastatic sites risks introducing confou... |
| 26.02.2025 | Perthera Report Pancreatic Version Now Available, Revolutionizing Chemo Selection for Pancreatic Cancer Treatment | First-of-Its-Kind AI Predictor Eliminates Guesswork in Frontline Chemotherapy Selection, Empowering Oncologists with Unprecedented Data-Driven Insights PRPv is not only improving chemotherapy selection, it’s accelerating precision oncology.... |
| 23.01.2025 | Perthera to Present Research Validating World’s First AI-Driven Chemo Predictor at 2025 ASCO GI Cancers Symposium | MCCLEAN, VA, UNITED STATES, January 23, 2025 /EINPresswire.com/ -- Perthera, a leader in precision oncology, will present follow-on research and validation of the world’s first AI-driven chemo predictor for frontline treatment in pancreatic... |
| 25.11.2024 | PERTHERA ANNOUNCES LANDMARK STUDY SHOWING MULTI-OMIC TESTING’S ROLE IN IMPROVING OUTCOMES FOR METASTATIC BREAST CANCER | MCLEAN, VA, UNITED STATES, November 25, 2024 /EINPresswire.com/ -- Perthera, the industry leader in Precision Oncology Decision Support, in collaboration with researchers from George Mason University and The Side-Out Foundation, announces t... |
| 07.11.2024 | Perthera, the Leading Therapeutic Intelligence Company, Releases vMTB 4.0, Accelerating AI Learning | MCLEAN, VA, UNITED STATES, November 7, 2024 /EINPresswire.com/ -- Perthera, the industry leader in Precision Oncology Decision Support, announces the release of the latest version of its patented Virtual Molecular Tumor Board application, v... |
| 08.02.2023 | Perthera.ai Announces a Category III CPT Code from the AMA for Its Patented Precision Oncology Decision Support Platform | The release of a Category III CPT code provides a critical pathway to reimbursement for Perthera’s AI-assisted decision support tool for oncologists. Perthera’s mission is to bring our industry-defining ranked therapy decision support to on... |
| 06.06.2022 | PERTHERA AI ANALYTICS LAUNCHES IMPROVED ANALYTICS, CLINICAL TRIAL OPTIMIZATION AND PATIENT CARE MANAGEMENT TOOL AT ASCO | Perthera AI’s proven data mining, analytics, optimization and care management platform now available for cancer centers to utilize for their own data analysis. 2 years ago, Perthera published a landmark study in Lancet Oncology that showed ... |
| 07.07.2016 | Startup Health: $3.9B in digital health funding for 2016's first half | Investment in digital health for the first half of 2016 has reached $3.9 billion, breaking funding records and showing a robust market that is expected to continue growing, according to a midyear report by digital health network and acceler... |
| 30.06.2016 | Perthera Secures $8.7M Investment | MCLEAN, VA, Perthera announced the completion of an $8.7 Million Series A financing. >> Click here for more funding data on Perthera >> To export Perthera funding data to PDF and Excel, click here Perthera, Inc. today ann... |
| 28.06.2016 | Perthera Secures $8.7 Million Investment from Pilot Growth Equity to Expand Global Leadership in Precision Cancer Analysis (“PCA”) | Funding will accelerate goal of becoming “the first step” whenever a patient is diagnosed with cancer MCLEAN, Va.–(BUSINESS WIRE)–June 28, 2016– Perthera, Inc. today announced the completion of an $8.7 Million Series A financing. Pilot Grow... |
Show more